Daily, Tue 3 Nov: Fresenius–WuXi biosimilars, uniQure Huntington's FDA date, Vaxcell liver cancer

Full transcript, with sources

Numbers in [brackets] link to the sources at the end of the section or episode. Chinese names are given in characters with Hanyu Pinyin; on air, Ning says them in Mandarin.

Opening

BasilA German group signs a Chinese partner for up to thirty-seven biosimilars. A Korean cell therapy reports liver cancer data. And a Huntington's gene therapy gets a US decision date. [1] [8] [10]

BasilI'm Basil Lui. I invest globally, backing growth-stage companies with an Asia angle, from Singapore. And this is The East-West Bio Brief. It's the daily edition for Tuesday, November third.

NingAnd I'm Ning. As always, these are our own voices, AI-cloned so we can bring you this every weekday morning. Personal views, not investment advice.

China

BasilLet's start in China. Ning, start with the deal.

Fresenius–WuXi Biologics biosimilars deal

NingGermany's Fresenius signed an exclusive deal with WuXi Biologics, in Chinese 药明生物 (Yàomíng Shēngwù), which develops biologic drugs for other companies. Fresenius gets options on up to thirty-seven biosimilars over the next decade. Those are close copies of biologic medicines. [1] [2]

NingThe first two copy Roche's Polivy and Amgen's Tepezza. Polivy is an antibody that carries a cell-killing drug into lymphoma cells, for the most common type of non-Hodgkin lymphoma. Tepezza is an antibody for thyroid eye disease, a rare autoimmune condition. It blocks a receptor linked to the disease, which helps calm the inflammation. [1] [2] (Polivy = polatuzumab vedotin, anti-CD79b antibody-drug conjugate for diffuse large B-cell lymphoma; Tepezza = teprotumumab, IGF-1R-blocking antibody.)

BasilFresenius calls it the largest development agreement in biosimilars to date. The Chinese side is paid a fee for service. [1]

Funding: Burgeon

BasilNext, the money.

NingBurgeon, in Chinese 博骥源 (Bójìyuán), a Shanghai drug developer, closed a Series A-plus of tens of millions of yuan. The money takes its eczema cream into a Phase Two-B trial. It's a non-steroid cream for atopic dermatitis, a chronic, itchy skin inflammation. It blocks a receptor on immune cells that drives inflammation. [3] [4] [5] (The cream is BGT-010, BGT-004 cream, a GPR84 antagonist; code name and target name left off air.)

Hong Kong listings

BasilOur next stop is Hong Kong.

NingAs we said on Monday, Hemay's books close tomorrow. One new date: Neautus, in Chinese 新荷花 (Xīn Héhuā), plans to list on November eleventh. It supplies decoction pieces, the sliced and processed herbs used in traditional Chinese medicine. [6] [7] [16] (Hemay's offer, closing Wed 4 Nov, was covered in the 2 Nov daily.)

BasilIt's not a pre-revenue biotech. It made a profit in each of the last three years. [6] [7]

Wider Asia

BasilLet's head beyond China. We start in Korea.

Korea: Vaxcell-Bio liver cancer cell therapy

NingVaxcell-Bio published early Phase Two results for a liver cancer cell therapy. It uses the patient's own natural killer cells, immune cells that seek out and attack cancer cells, alongside chemo infused straight into the liver's arteries. [8] (Therapy is VCB-1102; Phase 2a with hepatic artery infusion chemotherapy, locally advanced hepatocellular carcinoma.)

NingEleven of sixteen evaluable patients responded. Three had a complete remission. [8]

BasilIt's a small trial. The company now wants approval under Korea's advanced regenerative medicine law. That route lets hospitals treat patients under approved plans. [8]

Japan: BionicM

BasilNext, Japan.

NingTokyo's BionicM, which makes powered prosthetic legs, raised seven hundred and ten million yen in the first close of its Series B. Investors include B Dash Ventures and Mitsubishi U-F-J Capital. The money backs a US launch, in twenty twenty-seven, of a powered knee that helps the leg bend and straighten. [9] (Product: ASISTA, a microprocessor knee with flexion and extension assist; ¥710M includes earlier J-KISS convertible notes.)

Rest of the world

BasilNow, the rest of the world. We start in Washington.

FDA: uniQure Huntington's gene therapy

NingThe US Food and Drug Administration accepted uniQure's application for its Huntington's disease gene therapy, and granted it Priority Review. Huntington's is a fatal, inherited brain disease. The therapy is a one-time treatment, delivered by brain surgery, that silences the gene behind the disease. The decision date is May first, twenty twenty-seven. [10] [11] [12] (Therapy: ifezuntirgene inilparvovec, AMT-130; PDUFA target action date 1 May 2027; filed under accelerated approval.)

BasilThe agency is tentatively planning an advisory committee meeting. No date is set. [10]

Funding: Specific Biologics

BasilOne update on funding.

NingIn Toronto, Specific Biologics raised a thirty-five million US dollar Series A, led by Hatteras Venture Partners. Its gene-editing therapy is for A-L-S, the fatal disease that destroys the nerves controlling movement, speech, swallowing and breathing. It shortens a faulty run of repeated DNA in one gene, the most common known inherited cause of A-L-S. [13] (Gene: C9ORF72; platform: Dualase.)

East-West deep tech

BasilNow, deep tech. Robots need training data.

NingBeijing's GenRobot A-I raised a hundred million US dollars in a Series A-plus. It records people doing household, factory and logistics tasks, and turns those recordings into robot training data. Investors include S-A-I-C Motor, Baidu, Galaxy General Robotics and C-C-B International. [14] (Round closed in Q3, disclosed 2 Nov.)

BasilA carmaker, a search company and a robot maker all backed it. [14] (Hosts' observation.)

The mood

NingAnd the mood. On Monday morning, a Hang Seng Biotech E-T-F was down about two point one percent, and drug contract service stocks about three percent. The Hang Seng Index closed up about zero point four percent. [15] [17] (ETF and sector moves are intraday as of 10:06 HKT/SGT, 2 Nov; the index figure is the close.)

One thing to watch, call to action and sign-off

BasilMy one thing to watch is when the F-D-A sets that advisory committee date for the Huntington's therapy. [10]

BasilIf this brief is useful, follow The East-West Bio Brief on Spotify or Apple Podcasts.

NingAnd for the transcripts and sources, subscribe to our newsletter on LinkedIn, also called The East-West Bio Brief. It goes out every Sunday.

NingThat's today's brief. Every source is in the show notes. See you tomorrow.

[closing music]

Sources

1. Fresenius press release, 2 Nov 2026 — exclusive development agreement with WuXi Biologics: exclusive option rights for up to 37 biosimilar candidates over the next decade; "the largest development agreement announced in the biosimilars industry to date"; fee-for-service compensation per selected candidate; Fresenius holds global commercialisation rights; initial focus polatuzumab vedotin (ADC against CD79b on B cells, for diffuse large B-cell lymphoma, "the most common subtype of non-Hodgkin lymphoma") and teprotumumab (antibody that "binds to and inhibits" IGF-1R, for thyroid eye disease, "a rare autoimmune condition", helping "reduce the inflammatory and tissue-remodeling processes"). https://www.fresenius.com/Biopharma_Development_Agreement

2. Fierce Pharma, 2 Nov 2026 — initial focus on "Roche's blood cancer antibody-drug conjugate Polivy and Amgen's thyroid eye disease therapy Tepezza"; fee-for-service; WuXi offers development capabilities. https://www.fiercepharma.com/pharma/fresenius-expands-biosimilars-pipeline-37-asset-wuxi-deal-targeting-eur370b-market

3. 博望财经 / 猎云网, 2 Nov 2026 — 博骥源 (Burgeon) 数千万元 A+ round (勤智资本, 富汇创投, individual investors, existing shareholders); proceeds mainly for Phase IIb development of BGT-010; Shanghai company founded 2020. http://www.bowangcaijing.cn/news/1388102.html

4. 医药魔方 ByDrug, 9 Apr 2026 — BGT-010 is BGT-004 cream (乳膏), a topical GPR84 antagonist and non-steroid (非激素类) treatment for atopic dermatitis, "a chronic, relapsing, inflammatory skin disease" with intense itch; GPR84 is a pro-inflammatory receptor expressed on innate immune cells. https://bydrug.pharmcube.com/news/detail/a0a362a0e8c73000b568a7645aefabf1

5. 腾讯新闻, 29 Oct 2026 — first report of the Burgeon round. https://news.qq.com/rain/a/20261029A0300W00

6. etnet 經濟通 IPO page, 02206 新荷花 (Neautus) — subscription 30 Oct to 6 Nov, listing 11 Nov 2026; TCM decoction pieces (中藥飲片) supplier. https://www.etnet.com.hk/www/tc/stocks/ipo-info.php?code=2206

7. 制药网, 2 Nov 2026 — 新荷花 net profit RMB 104M (2023), 89.12M (2024), 106M (2025); Hemay offer 30 Oct to 4 Nov. https://www.zyzhan.com/news/detail/100702.html

8. Edaily, 2 Nov 2026 — Vaxcell-Bio's autologous NK cell therapy VCB-1102 with hepatic artery infusion chemotherapy (HAIC), Phase 2a, locally advanced hepatocellular carcinoma; paper in Cancer Research and Treatment (16 Oct); 11 of 16 evaluable patients responded (ORR 68.75%), 3 complete remission, 8 partial; NK cells "seek out and attack cancer cells"; HAIC injects drugs "directly into the arteries leading to the liver"; company seeking approval as the second treatment under the Advanced Regenerative Medicine Act, a route by which medical institutions treat patients "according to approved treatment plans". https://en.edaily.co.kr/news/eda202611025053/

9. PR TIMES (BionicM), 2 Nov 2026 — Series B 1st close ¥710M (7.1億円, incl. J-KISS), B Dash Ventures and 三菱UFJキャピタル; powered prosthetic legs; ASISTA knee with flexion and extension assist, US launch planned 2027; HQ Bunkyo, Tokyo. https://prtimes.jp/main/html/rd/p/000000020.000043008.html

10. uniQure press release, 2 Nov 2026 — FDA accepted the BLA for ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, Priority Review, PDUFA target action date 1 May 2027; FDA "tentatively planning to discuss this application at an Advisory Committee meeting", date not finalised; single administration via MRI-guided neurosurgical delivery; miRNA "designed to silence the huntingtin gene". https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics

11. GEN, 2 Nov 2026 — Huntington's disease described as "the fatal, inherited neurodegenerative disorder". https://www.genengnews.com/topics/genome-editing/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy/

12. BioBriefs, 2 Nov 2026 (briefing source; aggregator) — uniQure BLA acceptance, May 1 PDUFA under Priority Review. https://biobriefs.com/news/1

13. Specific Biologics press release (PR Newswire), 2 Nov 2026 — Toronto; oversubscribed US$35M Series A led by Hatteras Venture Partners; lead candidate shortens the C9ORF72 repeat expansion; C9ORF72 expansion is "the most common known inherited genetic cause of ALS"; ALS is "progressive and ultimately fatal… loss of motor neurons responsible for voluntary muscle movement, including speaking, swallowing and breathing". https://www.prnewswire.com/news-releases/specific-biologics-announces-oversubscribed-us35-million-series-a-financing-to-advance-gene-editing-therapy-for-als-302926076.html

14. TechNode, 2 Nov 2026 — Beijing-based GenRobot AI, US$100M Series A+ (closed Q3, disclosed 2 Nov); investors include SAIC Motor, Malaysia's Eastworlds, Baidu, Shoucheng Holdings, Galaxy General Robotics, GL Ventures, CITIC Goldstone, CCB International, Huatai Zijin; collects human demonstrations across household, manufacturing and logistics tasks to train robots. https://technode.com/2026/11/02/robot-training-data-startup-genrobot-ai-raises-100-million-in-series-a-funding/

15. NewTimeSpace, 2 Nov 2026, 10:19 — ChinaAMC Hang Seng Biotech ETF (03069.HK) down 2.10% intraday as of 10:06; pharmaceutical and biotech contract services sector down 3.24% and biotechnology down 2.00% in early trade while the Hang Seng Index rose. https://www.newtimespace.com/en/etf/1457882.html

16. The East-West Bio Brief daily, 2 Nov 2026 (callback) — "its books close this Wednesday" (Hemay). our episode page

17. RTHK, 2 Nov 2026, 17:31 HKT — Hang Seng Index closed up 0.42% at 23,393. https://news.rthk.hk/rthk/en/component/k2/1876246-20261102.htm

All sources were opened and checked against the script on Tuesday 3 November 2026 (SGT).